This marked effect of both the N106S and Y151A mutations of eIF6 in inhibiting growth of cancer cells further highlights the significance of targeting the eIF6–60S interaction interface as an effective strategy for cancer therapeutics. This evidence concerns the gene EIF6 and cancer.